ANDA 219999, held by Qilu Pharm Hainan. Carboplatin.
As of Nov 15, 2026, ANDA 219999 (Carboplatin), held by Qilu Pharm Hainan, was first approved by FDA on Feb 4, 2026, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 4, 2026 | Original application | Approved | None posted |
| Carboplatin50MG/5ML (10MG/ML) · injectable;intravenous | Carboplatin | Discontinued |
| Carboplatin150MG/15ML (10MG/ML) · injectable;intravenous | Carboplatin | Discontinued |
| Carboplatin450MG/45ML (10MG/ML) · injectable;intravenous | Carboplatin | Discontinued |
| Carboplatin600MG/60ML (10MG/ML) · injectable;intravenous | Carboplatin | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
